Pular para o conteúdo
Menu
Mix Vale

Research from the Karolinska Institute proves the durability of the HPV vaccine and requires extra doses in adulthood

Luís Henrique Costa
Por 5 min de leitura
Compartilhe
Vacina
Foto: Vacina - Foto: Jay_Zynism/istock

New scientific evidence consolidated by researchers from Instituto Karolinska, in Suécia, brought decisive confirmations about the prolonged effectiveness of immunization against the human papillomavirus. The study, which monitored the health of thousands of women over almost two decades, confirmed that the vaccine is highly efficient in preventing invasive cervical cancer. The data indicate a transformation in the global health scenario, suggesting that the protection generated by the vaccine is sustainable in the long term and eliminates the need for booster doses in adulthood for those vaccinated during childhood or adolescence.

Publicidade

The investigation followed the clinical trajectory of vaccinated and unvaccinated women between 2006 and 2023, using national health records to ensure data accuracy. Foi observed a direct and robust correlation between the age of vaccine administration and the reduction in the risk of developing tumors. Immunization not only prevents the initial viral infection, but effectively blocks the progression to serious oncological conditions, validating international strategies to eradicate the disease.

Vacina
ワクチン – 写真: Fernando Frazão/Agency Brasil

The results represent a significant advance for healthcare systems, as the reduction in invasive cases drastically reduces the demand for aggressive treatments, such as chemotherapy and complex surgical interventions. The proof that the vaccine maintains its potency for almost twenty years provides a solid basis for maintaining current vaccination schedules, which prioritize the administration of doses to girls and boys before the start of sexual life.

Publicidade

Impact of age on the effectiveness of immunization

Detailed analysis of records revealed that the impact of the vaccine reaches its maximum potential when administered before the age of 17. Neste specific group, the reduction in the risk of developing cervical cancer reached 79%, a figure that reinforces the strategic importance of vaccination campaigns in school and pediatric environments. Mesmo para as mulheres que receberam o imunizante tardiamente, entre os 17 e 30 anos, os benefícios foram evidentes, com uma diminuição do risco pela metade em comparação com o grupo não vacinado.

In addition to the drop in invasive cancer diagnoses, there was a substantial reduction in precancerous lesions, clinically classified as CIN2 and CIN3. Essas Cellular changes, when left untreated, have a high potential for evolving into malignant tumors. The prevention of these primary lesions is considered a crucial indicator of the success of health policy, as it interrupts the chain of development of the pathology in its initial stage. Comparison with birth cohorts prior to 1999, a period in which access to the vaccine was restricted, showed a clear contrast in the incidence of the disease.

The survey also addressed individual protection in relation to collective immunity. Mulheres vaccinated women had significantly lower infection and disease development rates than the non-immunized general population. The data suggests that the quadrivalent vaccine, the focus of analysis during the study period, establishes a robust biological barrier against the four most aggressive types of the virus.

Sustainability of immune protection

One of the most relevant findings of the Swedish study was the lack of decline in the immune response over time. Mesmo after 15 years of applying the doses, no evidence was detected that the body’s protection against the virus had decreased. Isso indica que a memória imunológica criada pela vacina é duradoura, eliminando, a princípio, a necessidade de revacinação ou doses de reforço na fase adulta para quem completou o esquema vacinal corretamente na juventude.

This finding has direct implications for public health budget management. By confirming that protection is permanent, governments can redirect resources that would be destined for booster doses to expand primary vaccination coverage, reaching populations that are still undiscovered. The focus of public policies remains on ensuring that children and adolescents aged 9 to 14 have access to the recommended doses, in line with the Organização Mundial and Saúde guidelines.

Publicidade

Medical experts point out that the stability of the immune response is a fundamental pillar for the eventual eradication of cervical cancer. Confidence in the longevity of protection allows screening programs, such as the Papanicolau test and HPV DNA tests, to be optimized. The focus becomes early detection in unvaccinated groups or rare vaccine failures, rather than monitoring a loss of immunity that data shows does not occur.

Prospects for global eradication

Although the research was conducted at Suécia, its findings reverberate globally, serving as a model for nations seeking to achieve the WHO goal of eliminating cervical cancer as a public health problem. The global target stipulates that 90% of girls are vaccinated by the age of 15. The Instituto Karolinska data serves as scientific validation that this objective is viable and highly effective for preserving life.

The reduction in the incidence of cancer also implies a reduced need for invasive medical procedures. Menos women will need to undergo hysterectomies, radiotherapy or treatments that compromise fertility and quality of life. Primary prevention through vaccination proves to be the most powerful and economical tool against oncogenic viral diseases.

The scientific community continues to monitor the data to verify the extent of protection throughout life, but the 18-year results are the most robust to date. Eles consolidate the medical consensus that the HPV vaccine is among the most successful health interventions of recent decades, capable of transforming a previously common and fatal disease into a rare and preventable condition.

Publicidade

Luís Henrique Costa é jornalista formado pela FMU, editor-chefe e fundador do Mix Vale, portal de notícias em atividade desde 2011. Responde pela direção editorial do veículo, que cobre Brasil e mundo em economia, benefícios sociais, esportes, tecnologia, ciência e entretenimento. Atua na área há mais de 15 anos e lidera uma equipe de cerca de 15 colaboradores.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto